Skip to main content
. 2022 Aug 28;13(5):1789–1827. doi: 10.1016/j.apsb.2022.08.020

Figure 9.

Figure 9

Schematic illustration of the delivery of CRISPR-Cas9 by MSC-derived EVs with immunosuppressive effects for neuroprotection. CRISPR/Cas9 loaded MSC EVs were modified with a targeting peptide, CAQK, to target activated macrophages in the spinal cord. Delivery of the CRISPR/Cas9 to these macrophages programed them to the M2 phenotype leading to neuroprotection effect. Reproduced with permission from Ref. 525. Copyright © 2022, Elsevier.